Journal profile · PHARMACOLOGY & PHARMACY
Drugs & Therapy Perspectives
ISSN 1172-0360 · eISSN 1179-1977 · Springer Nature
Drugs & Therapy Perspectives: CAS Zone 4 · Medicine (2025 upgraded edition); impact factor 0.6 (journal website); hybrid open access; APC about USD 3,490; median 56 days to acceptance (26 articles, last 24 months); 86 articles in 2025; indexed in ESCI and Scopus.
Scope
Aims, scope and focus
Drugs & Therapy Perspectives is published by Springer Nature and is in Zone 4 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Pharmaceutical studies and practices, Pharmacovigilance and Adverse Drug Reactions and Pharmaceutical Practices and Patient Outcomes, together about 32.3% of its articles. (generated from OpenAlex topic counts and CAS ranking data)
Drugs & Therapy Perspectives promotes rational pharmacotherapy and effective disease management by publishing concise, authoritative review articles to aid drug formulary and treatment decisions, and original research articles covering all aspects of pharmacological treatment to assist healthcare professionals in providing quality patient care. It focuses on the practical application of research and best evidence for healthcare professionals working in real-world clinical settings. The Journal includes: Reviews of pharmacological agents, disease management, adverse drug reactions and interactions, or other clinically relevant issues. These provide up-to-date guidance on the use of pharmacological agents in the real-world setting, including step-by-step patient care guidelines to aid treatment decisions, and the differential features of drugs to enable formulary comparisons. Original research articles with a strong focus on clinical practice and real-world outcomes to assist healthcare professionals in providing quality evidence-based patient care. Therapy-in-practice articles, current opinions and commentaries giving international viewpoints on emerging issues and therapeutic approaches to specific diseases or therapeutic questions.
From the journal's Aims & Scope
Research area (LetPub): PHARMACOLOGY & PHARMACY
Editor-in-chief Nitin Joshi BpharmPublisher website
Editorial board by country: 1 in mainland China (about 2%); most named United States 7, India 5, Australia 4, Portugal 4, Saudi Arabia 3 (44 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Pharmaceutical studies and practicesMedicine13.6%
- Pharmacovigilance and Adverse Drug ReactionsPharmacology, Toxicology and Pharmaceutics13.2%
- Pharmaceutical Practices and Patient OutcomesMedicine5.4%
- Pharmaceutical industry and healthcarePharmacology, Toxicology and Pharmaceutics4.2%
- Pharmacological Effects and Toxicity StudiesMedicine4.1%
- Asthma and respiratory diseasesMedicine4.1%
- Schizophrenia research and treatmentMedicine3.8%
- Economic, financial, and policy analysisEconomics, Econometrics and Finance3.8%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Pharmacology & Pharmacy | Zone 4 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Pharmacology & Pharmacy | Zone 4 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Not covered
Not covered by this edition.
Database indexing
ESCIScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Indexing the journal's website claims
EmbasePublisher website
Other: Google Scholar, EBSCO, ProQuest, Dimensions, CNKI, Baidu, Naver, OCLC, Portico, CLOCKSS
As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor (publisher) 2025
- 0.6Publisher website ·
- 5-year impact factor (publisher) 2025
- 0.6Publisher website ·
- CiteScore 2026-06
- 1LetPub ·
- SJR 2026-06
- 0.2LetPub ·
- SNIP 2026-06
- 0.18LetPub ·
- h-index
- 23OpenAlex ·
- i10-index
- 74OpenAlex ·
- 2-year mean citedness
- 0.57OpenAlex ·
- Self-citation rate
- 0%LetPub ·
- Share of gold OA articles
- 12.77%LetPub ·
Volume
- Articles per year
- 75LetPub ·
- Downloads per year (publisher) 2025
- 163,900Publisher website ·
Articles by year OpenAlex count · 3,603 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 64 | 64 | 4 |
| 2025 | 86 | 26 | 37 |
| 2024 | 86 | 34 | 94 |
| 2023 | 64 | 27 | 85 |
| 2022 | 89 | 45 | 257 |
| 2021 | 77 | 29 | 250 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with Crossref · to
56 daysMedian, submission to acceptance · P25–P75 38 days – 113 days
- Acceptance to online
- median 24 days (86 articles)
- Submission to online
- median 79 days
- Sample
- 26 articles with submission and acceptance dates (108 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Submission to first decision
- 8 daysPublisher website ·
- Peer review
- Double anonymous peer reviewPublisher website
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Hybrid open accessLetPub
A subscription journal in which authors can pay to publish their article open access.
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| OpenAlex | USD 3,490 / EUR 2,790 / GBP 2,390 | — | — |
A hybrid journal charges the APC only when the author chooses open access; publishing under the subscription model is usually free.
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
What to prepare4 items from the author guidelines
- Abstract
- 150–250 words
- Reference style
- Numbered, in order of citation
- Suggested reviewers
- Optional
- Cover letter
- Required
Article types accepted12
- editorialInternal Review by Editorial Staff: The journal editor will perform an initial appraisal of each manuscript. When submitting your paper, please include a coveri…Length not stated
- opinionThere is no limit on the number of tables, figures or references that can accompany an article. Information that is relevant but not critical to understanding t…Length not stated
- original researchThere is no limit on the number of tables, figures or references that can accompany an article. Information that is relevant but not critical to understanding t…Length not stated
- original research articleThere is no limit on the number of tables, figures or references that can accompany an article. Information that is relevant but not critical to understanding t…Length not stated
- perspectiveThere is no limit on the number of tables, figures or references that can accompany an article. Information that is relevant but not critical to understanding t…Length not stated
- protocolThere is no limit on the number of tables, figures or references that can accompany an article. Information that is relevant but not critical to understanding t…Length not stated
- research articleThere is no limit on the number of tables, figures or references that can accompany an article. Information that is relevant but not critical to understanding t…Length not stated
- reviewThere is no limit on the number of tables, figures or references that can accompany an article. Information that is relevant but not critical to understanding t…Length not stated
- review articleThere is no limit on the number of tables, figures or references that can accompany an article. Information that is relevant but not critical to understanding t…Length not stated
- short communicationThere is no limit on the number of tables, figures or references that can accompany an article. Information that is relevant but not critical to understanding t…Length not stated
- summary of research articleSummary of Research Article (SRA): A standalone summary of a source article previously published in an Adis journal, or in a journal from another publisher. The…Length not stated
- systematic reviewThere is no limit on the number of tables, figures or references that can accompany an article. Information that is relevant but not critical to understanding t…Length not stated
Policy excerpts from the journal's websiteAI use, Authorship, Conflicts of interest, Data availability, Publication ethics, License & copyright, Open access, Peer review, Trial registration / reporting guidelines
- AI use Generative AI Images
Please check Springer’s policy on generative AI images and make sure your work adheres to the principles described therein. Back to top
Source ↗Publisher website ·- Authorship Authorship Principles
These guidelines describe authorship principles and good authorship practices to which prospective authors should adhere to. Authorship clarified The Journal and Publisher assume all authors agreed with the content and that all gave explicit consent to submit and that they obtained consent from the responsible authorities at the institute/organization where the work has been carried out, before th…
Source ↗Publisher website ·- Conflicts of interest Disclosures and declarations
All authors are requested to include information regarding sources of funding, financial or non-financial interests, study-specific approval by the appropriate ethics committee for research involving humans and/or animals, informed consent if the research involved human participants, and a statement on welfare of animals if the research involved animals (as appropriate). The decision whether such …
Source ↗Publisher website ·- Data availability Data availability statements
Data availability statement required for original research Model summary
All original research must include a data availability statement. This statement should explain how to access data supporting the results and analysis in the article, including links/citations to publicly archived datasets analysed or generated during the study. Please see our full policy here. If it is not possible to share research data publicly, for instance when individual privacy could be com…
Source ↗Publisher website ·- Publication ethics
Originality and approval requirements Model summary
Submission of a manuscript implies: that the work described has not been published before; that it is not under consideration for publication anywhere else; that its publication has been approved by all co-authors, if any, as well as by the responsible authorities – tacitly or explicitly – at the institute where the work has been carried out.
Source ↗Publisher website ·- License & copyright Copyright and license term – CC BY-NC
Open Choice articles published under CC BY-NC 4.0 Model summary
Open Choice articles do not require transfer of copyright as the copyright remains with the author. In opting for open access, the author(s) agree to publish the article under the Creative Commons Attribution-NonCommercial 4.0 International License Find more about the license agreement Back to top
Source ↗Publisher website ·- Open access Open access publishing
To find out more about publishing your work Open Access in Drugs & Therapy Perspectives, including information on fees, funding and licences, visit our Open access publishing page. Back to top
Source ↗Publisher website ·- Peer review
Single-blind peer review with reviewer conflict disclosure Model summary
Peer reviewer identities are kept confidential, but author identities are known to the reviewers. Peer reviewers are asked to disclose potential conflicts of interests that may affect their ability to provide an unbiased review of an article.
Source ↗Publisher website ·- Trial registration / reporting guidelines Clinical Trial Registration
The World Health Organization (WHO) definition of a clinical trial is "any research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes". The WHO defines health interventions as “A health intervention is an act performed for, with or on behalf of a person or population whose purpose is to ass…
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Springer Nature
- ISSN
- 1172-0360
- Electronic ISSN
- 1179-1977
- Latest issue on the website
- Volume 42, Issue 1 (June 2026)
- Official links
- Journal homepage ↗OpenAlex
- Submission system ↗Publisher website
- Special issues ↗Publisher website
FAQ
Frequently asked questions about Drugs & Therapy Perspectives
What CAS zone is Drugs & Therapy Perspectives in?
In the 2025 upgraded edition of the CAS Journal Ranking, Drugs & Therapy Perspectives is in Zone 4 of Medicine, and in Zone 4 of the minor category Pharmacology & Pharmacy. In the 2026 Xinrui edition it is in Zone 4 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Drugs & Therapy Perspectives?
The journal's website gives an impact factor of 0.6 (2025); this is the journal's own figure, as LetPub lists none for it; CiteScore 1, h-index 23.
How long does peer review take at Drugs & Therapy Perspectives?
Based on the dates recorded on 26 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 56 days (interquartile range 38–113 days). Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
What are the manuscript requirements of Drugs & Therapy Perspectives?
According to the journal's author guidelines: Abstract: 150–250 words; Reference style: Numbered, in order of citation; Suggested reviewers: Optional; Cover letter: Required. A model extracted these from the author guidelines and each was checked against the text; check the latest version on the journal's website before submitting.
Where are the editorial board members of Drugs & Therapy Perspectives based?
Of the 44 board members whose country the journal's board page names, 1 (about 2%) are in mainland China; the countries named most often are United States (7), India (5) and Australia (4). Counted from the institutions listed on the board page; for reference only.
Which databases index Drugs & Therapy Perspectives?
According to LetPub and DOAJ records, Drugs & Therapy Perspectives is indexed in ESCI and Scopus. The journal's website also lists Embase; that list has not been checked against each database.
Is Drugs & Therapy Perspectives open access, and what is the APC?
Drugs & Therapy Perspectives is a hybrid journal. For open-access publication: APC about USD 3,490.
Sources and updates
The facts on this page come from LetPub, OpenAlex, Publisher website; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-24). Last updated: .